Q-omics provides the consensus-scored SLITRK6 profile across patient tissues and cancer cell-line models. SLITRK6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SLITRK6 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SLITRK6 RNA expression shows 13,809 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where SLITRK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLITRK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLITRK6 survival associations across molecular data types. SLITRK6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLITRK6 RNA expression–survival associations across cancer types. High SLITRK6 expression shows unfavorable associations in HNSC, KICH, KIRP, UVM and ACC, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SLITRK6 RNA expression.
This table summarizes SLITRK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLITRK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLITRK6 shows lower tumor expression in COAD, LIHC and STAD and higher tumor expression in UCEC, BRCA and KIRC. The COAD box plot shows higher SLITRK6 RNA expression in normal versus tumor tissue (log2 FC = −2.325, t-test p < 0.001).
This table shows molecular features associated with SLITRK6 in patient tissues and cancer cell lines. In patient samples, SLITRK6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLITRK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and URINARY_TRACT.
